Clinical Trials Directory

Trials / Completed

CompletedNCT01839448

Abnormal Post-partum Glucose Metabolism After Gestational Diabetes Diagnosed Before or After 24 Weeks of Gestation

Frequency of Abnormal Glucose Metabolism (Diabetes, Impaired Glucose Tolerance, Impaired Fasting Glucose) in the Immediate Postpartum Period Following Gestational Diabetes Diagnosed Before or After 24 Weeks of Gestation

Status
Completed
Phase
Study type
Observational
Enrollment
500 (actual)
Sponsor
Centre Hospitalier Universitaire de Nīmes · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

The main objective of the study is to estimate and compare the percentage of patients with abnormal glucose metabolism at 4-12 weeks postpartum between two groups: patients diagnosed with gestational diabetes before or after 24 weeks of pregnancy. Abnormal glucose metabolism is defined as type 2 diabetes, glucose intolerance or impaired fasting glucose.

Detailed description

The secondary objectives of this study are to compare between the two groups: A. the rate of type 2 diabetes only, glucose intolerance only, impaired fasting glucose only, and patients requiring insulin at 4-12 weeks postpartum B. rates of maternal and obstetric complications C. risk factors (age, body mass index, personal history of gestational diabetes or macrosomia, first degree family history of diabetes). D. For fasting glucose done before 24SA, we will calculate the optimal threshold for predicting abnormal glucose metabolism in the immediate postpartum period among women with gestational diabetes.

Conditions

Interventions

TypeNameDescription
BIOLOGICALPost-partum oral glucose tolerance testAll patients will have an oral glucose tolerance test at 4 to 12 weeks after the end of pregnancy. Study representatives will contact patients by phone to remind them of the necessity of this test, and its importance for their health.

Timeline

Start date
2014-03-27
Primary completion
2016-10-12
Completion
2016-10-12
First posted
2013-04-24
Last updated
2025-11-19

Locations

4 sites across 1 country: France

Source: ClinicalTrials.gov record NCT01839448. Inclusion in this directory is not an endorsement.